Cogent Biosciences Inc reports results for the quarter ended in March - Earnings Summary

Cogent Biosciences

07/05/2024 15:44

* Cogent Biosciences Inc  COGT.OQ  reported a quarterly
adjusted
loss of 62 cents​​ per share for the quarter ended in March,
lower than the same quarter last year, when the company reported
EPS of -54 cents.  The mean expectation of nine analysts for the
quarter was for a loss of 52 cents per share. Wall Street
expected results to range from -59 cents to -40 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cogent Biosciences Inc's reported EPS for the quarter was
a loss
of 62 cents​.
    * The company reported a quarterly loss of $58.35 million.
    * Cogent Biosciences Inc shares had risen by 12.6% this
quarter and gained 28.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.9%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cogent
Biosciences Inc is $17.00 
This summary was machine generated from LSEG data May 7 at 02:44
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.52          -0.62          Missed
 Dec. 31 2023      -0.56          -0.63          Missed
 Sep. 30 2023      -0.50          -0.64          Missed
 Jun. 30 2023      -0.54          -0.59          Missed